Volume 36, Issue 144 (October 2023)
IJN 2023, 36(144): 424-437 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Ehsani M, Seyedfatemi N, Haghani S, Abbasi A. Anxiety, Depression, and Post-traumatic Stress Disorder Symptoms in Patients Treated With Immunosuppressive Drugs During the COVID-19 Pandemic. IJN 2023; 36 (144) :424-437
URL: http://ijn.iums.ac.ir/article-1-3746-en.html
URL: http://ijn.iums.ac.ir/article-1-3746-en.html
1- Department of Medical Surgical Nursing, Nursing and Midwifery Care Research Center, Faculty of Nursing and Midwifery, Iran University of Medical Sciences, Tehran, Iran.
2- Nursing and Midwifery Care Reasearch Center, Faculty of Nursing and Midwifery, Iran University of Medical Sciences, Tehran, Iran.
3- Nursing and Midwifery Care Reasearch Center, Faculty of Nursing and Midwifery, Iran University of Medical Sciences, Tehran, Iran. ,abbasi.hojjat42@gmail.com
2- Nursing and Midwifery Care Reasearch Center, Faculty of Nursing and Midwifery, Iran University of Medical Sciences, Tehran, Iran.
3- Nursing and Midwifery Care Reasearch Center, Faculty of Nursing and Midwifery, Iran University of Medical Sciences, Tehran, Iran. ,
Abstract: (497 Views)
Background & Aims Despite the significant impact of immunosuppressive drugs on controlling and treating certain diseases, their continued use can predispose patients to infectious diseases such as COVID-19, leading to anxiety, depression, and post-traumatic stress disorder (PTSD) symptoms. This study aims to determine the levels of anxiety, depression, and PTSD symptoms in patients treated with immunosuppressive drug during the COVID-19 pandemic.
Materials & Methods This descriptive cross-sectional study was conducted on 330 individuals treated with immunosuppressive drug such as those with autoimmune diseases, cancer, and transplant recipients in Firoozgar and Rasoul-e-Akram hospitals in Tehran, Iran, from July to December 2022. They were selected using a continuous sampling method. The instruments were a demographic/disease-related questionnaire, the Hospital Anxiety and Depression Scale (HADS), and the Impact of Event Scale-Revised (IES-R). Data analysis was done in SPSS software, version 16 using descriptive (frequency, percentage, mean, standard deviation) and inferential (Independent t-test, analysis of variance, and Pearson’s correlation test) statistics.
Results In this study, the mean age of participants was 51.35±12.95 years, and 148 (44.8%) were female. The majority of the patients had normal levels of anxiety and depression (91.2% and 92.1%, respectively). The mean total IES-R score was 27.71 out of 88. The anxiety and depression scores did not have a significant relationship with any demographic, disease-related, and COVID-related characteristics of the study participants, but a significant correlation between income level and total score of IES-R was observed (P=0.043).
Conclusion The individuals receiving immunosuppressive drugs in this study, despite being susceptible to COVID-19, had normal levels of anxiety and depression and obtained lower than average score in the IES-R. This finding can reduce the concerns about the mental health of these patients. Further studies using other questionnaires or a qualitative study on the expriences of these patients during the COVID-19 pandemic are recommended.
Materials & Methods This descriptive cross-sectional study was conducted on 330 individuals treated with immunosuppressive drug such as those with autoimmune diseases, cancer, and transplant recipients in Firoozgar and Rasoul-e-Akram hospitals in Tehran, Iran, from July to December 2022. They were selected using a continuous sampling method. The instruments were a demographic/disease-related questionnaire, the Hospital Anxiety and Depression Scale (HADS), and the Impact of Event Scale-Revised (IES-R). Data analysis was done in SPSS software, version 16 using descriptive (frequency, percentage, mean, standard deviation) and inferential (Independent t-test, analysis of variance, and Pearson’s correlation test) statistics.
Results In this study, the mean age of participants was 51.35±12.95 years, and 148 (44.8%) were female. The majority of the patients had normal levels of anxiety and depression (91.2% and 92.1%, respectively). The mean total IES-R score was 27.71 out of 88. The anxiety and depression scores did not have a significant relationship with any demographic, disease-related, and COVID-related characteristics of the study participants, but a significant correlation between income level and total score of IES-R was observed (P=0.043).
Conclusion The individuals receiving immunosuppressive drugs in this study, despite being susceptible to COVID-19, had normal levels of anxiety and depression and obtained lower than average score in the IES-R. This finding can reduce the concerns about the mental health of these patients. Further studies using other questionnaires or a qualitative study on the expriences of these patients during the COVID-19 pandemic are recommended.
Type of Study: Research |
Subject:
nursing
Received: 2023/09/23 | Accepted: 2023/10/1 | Published: 2023/11/2
Received: 2023/09/23 | Accepted: 2023/10/1 | Published: 2023/11/2
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright © The Author(s);
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-By-NC), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Contact Information
